INTREPID SPINAL SYSTEM
K080083 · Medtronic Sofamor Danek · MAX · Apr 10, 2008 · Orthopedic
Device Facts
| Record ID | K080083 |
| Device Name | INTREPID SPINAL SYSTEM |
| Applicant | Medtronic Sofamor Danek |
| Product Code | MAX · Orthopedic |
| Decision Date | Apr 10, 2008 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The INTREPID™ Spinal System is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via a laparoscopic or an open anterior approach. The INTREPID™ interbody device is intended to be used with the three titanium alloy screws which accompany the implant. If the physician chooses to use less than three, or none of the provided screws, then additional supplemental fixation, which has been cleared by the FDA for use in the lumbar spine, must be used to augment stability.
Device Story
Stand-alone intervertebral body fusion device; anatomically shaped PEEK spacer with self-distracting nose; includes three titanium alloy screws for stabilization and back-out resistance. Implanted via laparoscopic or open anterior approach by surgeons. Provides structural support for fusion when used with autogenous bone graft. If fewer than three screws are used, requires additional FDA-cleared supplemental fixation. Benefits patients by stabilizing lumbar spine segments affected by degenerative disc disease.
Clinical Evidence
Bench testing only; no clinical data provided.
Technological Characteristics
Materials: PEEK (spacer) and titanium alloy (screws). Design: Anatomically shaped intervertebral body fusion device with self-distracting nose and integrated screw fixation. Mechanical stabilization via internal fixation screws.
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels (L2-S1), including those with up to Grade 1 Spondylolisthesis or retrolisthesis, who have failed six months of non-operative treatment.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
*Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
- SynFIX-LR Spacer (K072253)
- LT-CAGE® Peek Lumbar Tapered Fusion Device (P970015)
- BAK® Cage (P950002)
- RAY® Threaded Fusion Cage (P950019)
- Lumbar I/F Cage (P960025)
- PARAMOUNT Intervertebral Body Fusion Device (K072120)
Related Devices
- K152943 — NuVasive Foundation-LL System · Nu Vasive, Incorporated · Dec 1, 2015
- K112561 — NUVASIVE COROENT NO-PROFILE SYSTEM · Nuvasive, Inc. · Mar 13, 2012
- K181386 — NuVasive Brigade Lateral System · Nu Vasive, Incorporated · Aug 24, 2018
- K123045 — BRIGADE STANDALONE SYSTEM · Nuvasive, Inc. · Apr 16, 2013
- K203742 — IdentiTi ALIF Standalone Interbody System · Alphatec Spine, Inc. · Apr 9, 2021
Submission Summary (Full Text)
{0}------------------------------------------------
Page 1 of 2
## INTREPIDTM Spinal System 510(k) Summary March 2008 - K080083
APR 1 0 2008
- Medtronic Sofamor Danek Company: l. 1800 Pyramid Place Memphis, TN 38132 (901) 396-3133
Contact: Lee Grant Senior Project Specialist, Regulatory Affairs
### Proprietary Trade Name: INTREPID™ Spinal System II.
- Classification Name/Product Code: Intervertebral Body Fusion Device (21 CFR III. 888.3080)
- Product Code: MAX IV.
#### Product Description V.
The INTREPID™ Spinal System is a stand-alone intervertebral body fusion device, which consists of an anatomically shaped vertebral body spacer designed with a selfdistracting nose. The spacer is equipped with three holes which allow for the placement of internal fixation screws. The screws are inserted through the cage and help provide stabilization and back-out resistance. The INTREPID™ spacer is manufactured from medical grade polyetheretherketone (PEEK), while the screws are manufactured from titanium alloy.
#### V. Indications
The INTREPID™ Spinal System is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via a laparoscopic or an open anterior approach.
The INTREPID™ interbody device is intended to be used with the three titanium alloy screws which accompany the implant. If the physician chooses to use less than three, or none of the provided screws, then additional supplemental fixation, which has been cleared by the FDA for use in the lumbar spine, must be used to augment stability.
{1}------------------------------------------------
# K080083
### VI. Substantial Equivalence
Documentation, including mechanical test results was provided which demonstrated that the subject INTREPID™ Spinal System is substantially equivalent to the SynFIX-LR Spacer (K072253, SE 10/12/07, Synthes Spine), the LT-CAGE® Peek Lumbar Tapered Fusion Device (P970015, Medtronic Sofamor Danek, Approved 9/10/03), the BAK® Cage (P950002, Zimmer Spine, Approved 7/8/03), the RAY® Threaded Fusion Cage (P950019, Stryker, Approved 9/4/03), the Lumbar I/F Cage (P960025, DePuy, Approved 3/4/05) and the PARAMOUNT Intervertebral Body Fusion Device (K072120, Innovative Spinal Technologies, SE 10/11/07).
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular fashion around the eagle. The eagle is depicted in a simple, black and white design.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
# APR 1 0 2008
Medtronic Sofamor Danek % Mr. Lee Grant Senior Project Specialist, Regulatory Affairs 1800 Pyramid Place Memphis, TN 38132
Re: K080083
Trade/Device Name: INTREDPID™ Spinal System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: II Product Code: MAX Dated: January 8, 2008 Received: January 11, 2008
Dear Mr. Grant:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
### Page 2 - Mr. Lec Grant
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Mark N. Millerson
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
510(k) Number (if known): K080083
Device Name: INTREPID™ Spinal System
### Indications for Use:
The INTREPID™ Spinal System is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via a laparoscopic or an open anterior approach. The INTREPID™ interbody device is intended to be used with the three titanium alloy screws which accompany the implant. If the physician chooses to use less than three, or none of the provided screws, then additional supplemental fixation, which has been cleared by the FDA for use in the lumbar spine, must be used to augment stability.
Prescription Use X (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Nul he Qgl formxm
(Division Sign-Division of General, Restorative, and Neurological Devices
AND/OR
510(k) Number K080083